✨ Free AI Report
OSE Immunotherapeutics: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research OSE Immunotherapeutics
Company Research

OSE Immunotherapeutics: Business Overview, Financials & Competitive Analysis

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and immuno-inflammation. The company's lead assets, lusvert...

Analyst-debate audio for OSE Immunotherapeutics

AskCyborg analysts argue the bull and bear cases for OSE Immunotherapeutics across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Mixed

Cyborg Score thesis

European biotech with late-stage clinical catalysts and strategic partnerships, but requires successful Phase 3 outcomes and...

Read the full analyst-debate transcript →
Industry Biotechnology - Clinical-stage immunotherapies (Immuno-Oncology and Immuno-Inflammation)
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest OSE Immunotherapeutics Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

OSE Immunotherapeutics Overview

Pro stress-test →

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and immuno-inflammation. The company's lead assets, lusvertikimab and Tedopi®, hold the potential to redefine standards of care across multiple diseases in immuno-inflammation and immuno-oncology.

Strategic Profile

Pro stress-test →

As of March 2026, the company has announced a targeted realignment of its R&D portfolio, pausing development of OSE-230 to focus resources on late-stage, high-potential assets lusvertikimab and Tedopi®. These two assets are expected to generate multiple clinical catalysts over the next three years. The company continues to explore various options, including business development, strategic alliances, international investments, and a potential Nasdaq listing.

Competitive Landscape

Pro stress-test →

OSE competes with biotech firms including Innate Pharma, Immatics, ImmunityBio, Aura Biosciences, and Transgene. OSE differentiates through proprietary immune-modulation platforms targeting both immune activation (immuno-oncology) and suppression (immuno-inflammation), with clinical programs in late-stage development backed by European partnerships.

Industry Context

OSE Immunotherapeutics operates in Biotechnology - Clinical-stage immunotherapies (Immuno-Oncology and Immuno-Inflammation).

Key facts

Founded: 2016 · Headquarters: Nantes, France · Employees: 65 · Revenue: $2.31M · Market cap: $162M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on OSE Immunotherapeutics.

  • March 2026: Portfolio streamlining with focus on two cornerstone assets—lusvertikimab for inflammatory indications and Tedopi® cancer vaccine for NSCLC.
  • Significant clinical catalysts expected 2026-2028: Tedopi ovarian cancer Phase 2 readout (Q2 2026), NSCLC Phase 3 interim analysis (Q3 2026), lusvertikimab subcutaneous formulation (H1 2027).
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Announced strategic portfolio realignment focusing on lusvertikimab and Tedopi®, pausing OSE-230 development
  • January 2026Selected chronic pouchitis and hidradenitis suppurativa as new target indications for lusvertikimab
  • +2 moreTrack every material event for OSE Immunotherapeutics as it happens. Explore monitoring →
Get alerted when OSE Immunotherapeutics has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Various immuno-oncology programsFrench competitor developing immunotherapies→T-cell redirecting therapiesCell therapy and immunotherapy development→CAR-NK and checkpoint inhibitor combosCell and checkpoint immunotherapy company→Novel oncology immunotherapiesEuropean biotech with oncology focus→

Compare OSE Immunotherapeutics with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

OSE Immunotherapeutics operates in Biotechnology - Clinical-stage immunotherapies (Immuno-Oncology and Immuno-Inflammation). See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Clinical-stage immunotherapies (Immuno-Oncology and Immuno-Inflammation) research →
NEW · MCP server

Ask your AI assistant about OSE Immunotherapeutics

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare OSE Immunotherapeutics and its top competitor on Cyborg Score”
“What did OSE Immunotherapeutics do this quarter?”
“Is OSE Immunotherapeutics a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does OSE Immunotherapeutics do?+
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and immuno-inflammation. The company's lead assets, lusvert...
What is OSE Immunotherapeutics's Cyborg Score?+
OSE Immunotherapeutics has a Cyborg Score of 6/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are OSE Immunotherapeutics's main competitors?+
Named competitors include Various immuno-oncology programs, T-cell redirecting therapies, CAR-NK and checkpoint inhibitor combos, Novel oncology immunotherapies. The full competitive landscape is in the AskCyborg report.
How can I get the full OSE Immunotherapeutics research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the OSE Immunotherapeutics research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track OSE Immunotherapeutics over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.